Ionis Pharmaceuticals (IONS) Cash & Equivalents (2009 - 2026)

Ionis Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $173.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 34.37% year-over-year to $173.4 million in Q1 2026; TTM through Mar 2026 was $173.4 million, a 34.37% decrease from a year earlier, with the FY2025 full-year figure at $372.3 million, up 53.78% from the prior year.
• Cash & Equivalents declined to $173.4 million in Q1 2026 per IONS's latest filing, from $372.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $542.5 million in Q1 2022 and bottomed at $173.4 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $334.6 million (2024), against an average of $341.5 million.
• Across the five-year window, Cash & Equivalents sank 68.19% in 2022 and jumped 53.78% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $276.5 million in 2022, then soared by 44.41% to $399.3 million in 2023, then plunged by 39.37% to $242.1 million in 2024, then soared by 53.78% to $372.3 million in 2025, then slumped by 53.42% to $173.4 million in 2026.
• Per Business Quant, the three latest IONS Cash & Equivalents figures stand at $173.4 million (Q1 2026), $372.3 million (Q4 2025), and $338.3 million (Q3 2025).